ArticleClinical and translational medicine2021
The oral KIF11 inhibitor 4SC-205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models.
Abstract readLetter
In one paragraph
Article in Clinical and translational medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Natural Product Target Identification of Wheldone, a Fungal Metabolite, as a KIF11 Inhibitor in Ovarian Cancer Using the DiffPOP (Differential Protein Precipitation) Method.Molecular & cellular proteomics : MCP · 2026Article
- Kinesin Spindle Protein (KIF11) in Mitosis and Cancer.International journal of molecular sciences · 2025Review
- The two sides of chromosomal instability: drivers and brakes in cancer.Signal transduction and targeted therapy · 2024Review
- Kinesin family member 11 promotes progression of hepatocellular carcinoma via the OCT4 pathway.Functional & integrative genomics · 2023Article
- Improving Localized Radiotherapy for Glioblastoma via Small Molecule Inhibition of KIF11.Cancers · 2023Article
- Design, synthesis and biological evaluation of 2,4-pyrimidinediamine derivatives as ALK and HDACs dual inhibitors for the treatment of ALK addicted cancer.Journal of enzyme inhibition and medicinal chemistry · 2022Article
- Structural disruption of BAF chromatin remodeller impairs neuroblastoma metastasis by reverting an invasiveness epigenomic program.Molecular cancer · 2022Article
- Identification and verification of hub genes associated with the progression of non-small cell lung cancer by integrated analysis.Frontiers in pharmacology · 2022Article
- Patient-derived models: Advanced tools for precision medicine in neuroblastoma.Frontiers in oncology · 2022Review
- Leveraging Kinesin Family as Key Regulators of Malignant Progression and the Immunometabolic Niche for Precision Oncology.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Marc MasanasGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Nuria MasiáCell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Leticia Suárez-CabreraCell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Mireia OlivanCell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Aroa SorianoGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Blanca MajemCell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Laura Devis-JaureguiMolecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Rebeca Burgos-PanaderoGroup of Translational Research in Pediatric Solid Tumors Department of Pathology, Medical School, University of Valencia-INCLIVA Biomedical Health Research Institute, Valencia, Spain.
Carlos JiménezGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Pau Rodriguez-SodupeQuantitative Genomic Medicine Laboratory, qGenomics, Barcelona, Spain.
Ariadna BoloixGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Ignasi ToledanoCell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Gabriela GuillénGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Alexandra NavarroDepartment of Pathology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
David Llobet-NavasMolecular Mechanisms and Experimental Therapy in Oncology-Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Spain.
Alberto VillanuevaGroup of Chemoresistance and Predictive Factors, Subprogram Against Cancer Therapeutic Resistance (ProCURE), ICO, Oncobell Program, IDIBELL, L'Hospitalet del Llobregat, Barcelona, Spain.
Josep Sánchez de ToledoGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Josep RomaGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Rosa NogueraGroup of Translational Research in Pediatric Solid Tumors Department of Pathology, Medical School, University of Valencia-INCLIVA Biomedical Health Research Institute, Valencia, Spain.
Lucas MorenoGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Rolf Krauss4SC, Martinsried, Germany.
Soledad GallegoGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Anna SantamariaCell Cycle and Cancer Laboratory, Biomedical Research Group in Urology, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.
Miguel F SeguraGroup of Translational Research in Child and Adolescent Cancer, Vall d'Hebron Research Institute (VHIR) - Universitat Autònoma de Barcelona (UAB), Barcelona, Spain.ORCID 0000-0003-0916-3618
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Administration, OralAnimalsAntineoplastic AgentsCell Line, TumorDisease Models, AnimalHumansKinesinsMiceNeuroblastomaAntineoplastic AgentsKIF11 protein, humanKinesins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.